

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 39151

Manuscript Type: MINIREVIEWS

**Advances in immuno-oncology biomarkers for gastroesophageal cancer:
 Programmed death ligand 1, microsatellite instability, and beyond**

Lin EM *et al.* Immuno-oncology biomarkers for gastroesophageal cancer

Emily M Lin, Jun Gong, Samuel J Klempner, Joseph Chao

Abstract

Blockade of the programmed death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) receptor axis represents an effective form of cancer immunotherapy. Preclinical evidence initially suggested that gastric and gastroesophageal junction (GEJ) cancers are potentially immunotherapy-sensitive tumors. Early phase clinical trials have demonstrated promising antitumor activity with PD-1/PD-L1 blockade in advanced or

Match Overview

1	Internet 46 words crawled on 06-Jun-2018 jgo.amegroups.com	1%
2	Crossref 30 words Festino, Lucia, Gerardo Botti, Paul Lorigan, Giuseppe V. Masucci, Jason D. Hipp, Christine E. Horak, Ignacio Mel	1%
3	Crossref 25 words Charles S. Fuchs, Toshihiko Doi, Raymond W. Jang, Kei Muro et al. "Safety and Efficacy of Pembrolizumab Monot	<1%
4	Internet 21 words crawled on 26-Sep-2017 voice.ons.org	<1%
5	Internet 18 words crawled on 30-Jul-2017 dl.kums.ac.ir	<1%
6	Internet 18 words crawled on 18-Feb-2018 www.infona.pl	<1%
7	Crossref 17 words Junhun Cho, Jeeyun Lee, Heejin Bang, Seung Tae Kim et al. "Programmed cell death-ligand 1 expression prec ...	<1%
8	Internet 16 words crawled on 18-Oct-2017 tcr.amegroups.com	<1%
9	Internet 15 words crawled on 21-Jun-2017 www.endocrine.org	<1%

找到约 11,900 条结果 (用时 0.53 秒)

[PDF] Bringing the Next Generation of Immuno-Oncology Biomarkers ... - M...

www.mdpi.com/2227-9059/6/1/14/pdf  [翻译此页](#)

作者: A Cesano - 2018

2018年2月2日 - recurrent or metastatic head and neck cancer, refractory classical Hodgkins lymphoma, urothelial carcinoma, **gastric cancer**, and cancers with a **biomarker** referred to as high microsatellite instability. (MSI-H). For these therapies (with the exception of the latter), **PD-L1** IHC has been the primary diagnostic ...

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635257/> - [翻译此页](#)

作者: KR Voong - 2017 - 被引用次数: 5 - 相关文章

Recently, a firmer understanding of **tumor immunology** and **tumor** escape mechanisms has led to the development of **immune** checkpoint inhibitors, antibodies against programmed death-1 (**PD-1**) and its ligand (**PD-L1**). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in ...

[PDF] Approval of pembrolizumab (MSI-H/dMMR) and considerations for si...

www.ema.europa.eu/docs/en_GB/document_library/.../WC500243479.pdf  [翻译此页](#)

Some mutations (neo-antigens) may be targeted by **immune** system. • Pembrolizumab can facilitate **immune** system response in some **MSI-H/dMMR** cancers ... **Esophageal cancer**. 1. **PR**. **Sarcoma**. 1. **PD**. **Thyroid cancer**. 1. **NE**. **Retroperitoneal adenocarcinoma**. 1. **PR**. **Small cell lung cancer**. 1. **CR**. **Renal cell cancer**. 1. **PD**.

Combined prognostic effect of PD-L1 expression and immunoscore in ...

www.oncotarget.com/fulltext/19439  [翻译此页](#)

作者: KJ Kim - 2017 - 被引用次数: 1 - 相关文章

2017年8月29日 - Combined prognostic effect of **PD-L1** expression and immunoscore in microsatellite-unstable advanced **gastric cancers**. ... Therefore, **MSI-H** GCs are thought to provide an adequate platform for the evaluation of the relevance of tumor infiltrating **immune** cells and **PD-L1** expression. In the current study, we ...

[PDF] Current status of immunotherapy and immune biomarkers in gastro...



Correlation of benefit from immune checkpoint inhiAdvances in immuno-



全部

新闻

图片

购物

地图

更多

设置

工具

找到约 5 条结果 (用时 0.52 秒)

您是不是要找: **Correlation of benefit from immune checkpoint *in Advances* in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond**

Is There a Role for Programmed Death Ligand-1 Testing and ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29144791> - 翻译此页

作者: EC Marginean - 2018 - 被引用次数: 1 - 相关文章

Part I-Colorectal **Cancer: Microsatellite Instability**, Testing, and Clinical Implications. ... Department of Medical **Oncology**, University of British Columbia, Vancouver, ... Microsatellite status has been recognized as a prognostic and predictive **biomarker**. ... **immune** response, **programmed death** receptor-1/**programmed death** ...

Programmed death-ligand 1 is a promising blood marker for predicting ...

<https://www.ncbi.nlm.nih.gov/pubmed/29345842> - 翻译此页

作者: M Amatatsu - 2018 - 被引用次数: 1

2018年2月19日 - 1. **Cancer Sci.** 2018 Mar;109(3):814-820. doi: 10.1111/cas.13508. ... for predicting tumor progression and prognosis in patients with **gastric cancer**. ... **death-ligand 1 (PD-L1)** are widely known as important **immune checkpoint** ... In addition, liquid biopsy of blood specimens has the clinical **benefit** of providing ...

Characterization of biomarkers to immune checkpoint blockade ...

ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.26 - 翻译此页

作者: M Russell - 2018

2018年2月26日 - Currently, **tumor** expression of **programmed death-ligand 1 (PD-L1)** is clinically ... However, across solid tumors, only a subset of patients **benefit** from ICBs, ... gene-fusions in 435 **cancer-related** genes, **microsatellite instability (MSI)**, ... The **relationship** between PD-L1 expression and the other **biomarkers** ...

Frequent programmed death-ligand 1 expression in gastric cancer ...

ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e15579 - 翻译此页

作者: C Ma - 2016 - 被引用次数: 1 - 相关文章

Background: **Immune checkpoint** blockade of the **programmed death ligand 1** ... Therefore development



找到约 26,600 条结果 (用时 0.48 秒)

Google 学术: Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond

... biomarker research for PD-1/PD-L1 immune ... - Ma - 被引用次数: 123

... and immune correlates of anti-PD-1 antibody in cancer - Topalian - 被引用次数: 6512

PD-1 blockade in tumors with mismatch-repair ... - Le - 被引用次数: 2447

[PDF] Bringing the Next Generation of Immuno-Oncology Biomarkers ... - M...

www.mdpi.com/2227-9059/6/1/14/pdf ▼ 翻译此页

作者: A Cesano - 2018 - 被引用次数: 1

2018年2月2日 - death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1), ... Thanks to the rapid progress in technology, today we can measure ... carcinoma, gastric cancer, and cancers with a biomarker referred to as high microsatellite instability ... Beyond the issues with current PD-L1 IHC assays, PD-L1 as a ...

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non ...

atm.amegroups.com/article/view/16544/html ▼ 翻译此页

作者: KR Voong - 2017 - 被引用次数: 7 - 相关文章

¹ Department of Radiation Oncology and Molecular Radiation Sciences, ... antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). ... Table 1 Emerging tissue-based biomarkers of immune checkpoint inhibitor response tumor-node-metastasis (TNM) staging system and microsatellite instability status (50).

Biomarkers for immunotherapy in bladder cancer: a moving target ...

<https://link.springer.com/article/10.1186/s40425-017-0299-1> - 翻译此页

作者: DH Aggen - 2017 - 被引用次数: 7 - 相关文章

... University Medical Center Hematology/Oncology New York USA ... Bladder cancer PD-1 Pd-L1 Immunotherapy Atezolizumab Nivolumab ... Tumor mutation burden Immune checkpoint inhibitor Biomarker Nanostring ... Microsatellite instability ... PD-1. Programmed cell death protein 1. PD-L1. Programmed death ligand 1.